AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03223831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Partially covered pyloro-duodenal stent
Description: The PCDS (Niti-S COMVITM - Flare, Taewoong, Gyeonggi-do, South Korea) used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions (Figure 1). The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. This is designed to provide anchorage of the stent to surrounding tissue and reduce the risk of migration. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh to prevent the risk of tumour ingrowth into the stent. The stents come in lengths of 6, 8, 10 \& 12cm.
Study NCT03223831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered pyloro-duodenal stents
Description: The UCDS (Niti-S pyloric-duodenal D stent, Taewoong, Gyeonggi-do, South Korea) used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm and length of 6,8,10,12cm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
Study NCT03950700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: BUPIROP® 0.5% ROPSOHN THERAPEUTICS S.A.S
Study NCT03950700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline solution 0.9% (Baxter laboratories).
Study NCT04355377 — intervention group
Intervention type: OTHER
Intervention: Non intervention
Description: Non intervention
Study NCT01291940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Moisturizer
Description: Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
Study NCT01291940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adult Moisturizer
Description: Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
Study NCT00384189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: inhaled Ciclesonide
Study NCT00384189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Ciclesonide placebo-matching inhaler
Study NCT00384189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ciclesonide placebo-matching inhaler
Study NCT00384189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol inhalation powder
Study NCT00384189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol inhalation powder
Study NCT00696943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ([18F]-ML-10)
Description: \[18F\]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of \[18F\]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
Study NCT02106962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid 5% with bacitracin
Description: Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
Study NCT02106962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid 25% with bacitracin
Description: Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
Study NCT01552226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Preperitoneal Analgesia
Description: Preperitoneal catheter placed at the completion of surgery in the standard fashion.
Study NCT01552226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Epidural Analgesia
Description: Epidural catheter placed prior to the operation in the standard fashion.
Study NCT00248651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.
Study NCT00248651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.
Study NCT00248651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
Study NCT00765856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER
Description: Oxymorphone ER dosing adjustments made under the direction of the Investigator during the Titration Period.~Oxymorphone IR (Opana) IR 5mg tablet - used as rescue medications
Study NCT03012932 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HPV self-sampling
Description: All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
Study NCT01365130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: jevtana
Description: Cabazitaxel 25mg/m2, IV every 21 days until progression
Study NCT03065647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expedited Transport With Mechanical CPR
Description: Patients with OHCA refractory to initial BLS and ACLS will be transported by EMS with ongoing mechanical CPR and ACLS to an emergency department capable of initiating ECPR.
Study NCT04110353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressings: Conservative dressings
Description: Conservative dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
Study NCT02529930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.16 Immunotherapy (DNA vaccine)
Description: Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
Study NCT00714974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS
Description: Sedation dosing based on BIS value, oer treating physician discretion.
Study NCT02571556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
Description: Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
Study NCT03923153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training with PowerBreathe (IMT Technologies Ltd., Birmingham,England)
Description: Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department.
Study NCT03923153 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham group with PowerBreathe (IMT Technologies Ltd., Birmingham, England)
Description: Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 10% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department.
Study NCT01691378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Window to Hope
Description: Psychotherapy - Group
Study NCT04110353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressings: Prevena dressings
Description: Prevena dressing to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
Study NCT04110353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressings: ciVAC dressings
Description: Closed incision VAC dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
Study NCT01510080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted live supervision
Description: 8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients
Study NCT01510080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed video-based supervision
Description: 12 video-based sessions (each 50 minutes) during treatment of 2 patients
Study NCT03236584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine plus adefovir combination
Description: continuing lamivudine plus adefovir
Study NCT03236584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: switching to tenofovir
Study NCT01541384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitality GlowCaps
Description: The main research instrument is an electronic pill bottle called GlowCaps that has the ability to transmit reminder messages via email, text, and phone to the subject, and adherence data to special servers. The messages will be sent twice a day, if a subject misses a dose of their immunosuppression medication (tacrolimus). Each time the pill bottle is opened (or not opened), a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network. No extra cellular or wireless service is required from subjects for the GlowCap to function.~Note: GlowCaps are a Class 1 Medical Device registered with the FDA. Because of this Class 1 designation, they are not subject to FDA testing or approval.
Study NCT01541384 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vitality GlowCaps
Description: The main research instrument is an electronic pill bottle called GlowCaps that has the ability to transmit reminder messages via email, text, and phone to the subject, and adherence data to special servers. The messages will be sent twice a day, if a subject misses a dose of their immunosuppression medication (tacrolimus). Each time the pill bottle is opened (or not opened), a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network. No extra cellular or wireless service is required from subjects for the GlowCap to function.~Note: GlowCaps are a Class 1 Medical Device registered with the FDA. Because of this Class 1 designation, they are not subject to FDA testing or approval.
Study NCT05215964 — intervention group
Intervention type: PROCEDURE
Intervention: Renal artery embolization
Description: After catheterization of renal arteries, multiple coils are applied to embolize renal arteries until blood flow stasis
Study NCT03203330 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TG-C
Description: 2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
Study NCT03203330 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: 2 mL normal saline injection
Study NCT05293977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine care by the dispensing pharmacist
Description: Patients in the control group received routine care by the dispensing pharmacist and seen by research assistant for data collection only
Study NCT05293977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical education/counseling about prescribed antibiotic
Description: Patient in the intervention group was provided with pharmaceutical education about his/her prescribed antibiotic by the trained clinical pharmacist. To prepare the education about antibiotics, the 10 most commonly prescribed antibiotics were determined in advance from hospital records: Amoxicillin or Amoxicillin/Clavulanic acid, Ciprofloxacin, Levofloxacin, Azithromycin, Cefuroxime, Cephalexin, Clindamycin, Doxycycline, Metronidazole, Trimethoprim/Sulfamethoxazole. Standard education points about antibiotics include (i) mechanism of action and/or use, (ii) correct administration method, (iii) correct timing, (iv) possible adverse effect and self-management intervention methods when faced with side effects, (v) what to do in case of missing any dose.
Study NCT00565773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept will be given within 24 hours of transplantation via a peripheral intravenous catheter at a dose of 10mg/kg (actual body weight) infused over 30 mins. The dose will be repeated on study days 4 (post op day 3) and 8 (post op day 7), then every 2 weeks for 5 additional doses. Thereafter, belatacept will be given once every 4 weeks (+/- 3 days) at 10mg/kg through 6 months then at 5mg/kg indefinitely.
Study NCT00565773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be started on postoperative day 1 at a dose of 2 mg per day orally. Doses will be adjusted to maintain 24-hour trough levels of 8-10ng/ml until the drug is weaned. Toxicity attributable to sirolimus (e.g., mouth ulcers, arthralgias) will prompt dose reduction to address clinical concerns in this regard. If sirolimus trough levels need to be reduced below 4ng/ml to control drug side effects, the patient will be considered intolerant to the drug and will be changed to other medications.
Study NCT00565773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: All participants will receive a single dose of 30 mgs of alemtuzumab on the day of transplantation.
Study NCT04562766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: 400mg Caplet
Study NCT04562766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg Caplet
Study NCT01691378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
Study NCT00417664 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Dexmedetomidine administered as part of anesthesia in cardiac surgery patients
Study NCT00417664 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Propofol administered as part of anesthesia in cardiac surgery patients
Study NCT00417664 — intervention group
Intervention type: DRUG
Intervention: Midazolam
Description: Midazolam administered as part of anesthesia in cardiac surgery patients
Study NCT05739487 — intervention group
Intervention type: PROCEDURE
Intervention: selective intra-arterial thrombolysis
Description: IAT introduces rt-PA (50mg) directly into the ophthalmic circulation by super-selective microcatheterization
Study NCT03177148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention by Clinicians
Description: •Parents will complete surveys after enrollment and at the end of intervention and participate in intervention visits by pediatric clinicians and telephonic counseling with Registered Dietitians (RDs).~Intervention by pediatric clinicians: up to 4 sessions of MI, in-person Intervention by RDs: up to 6 sessions of MI via telephone.
Study NCT03177148 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Pediatric clinicians provide care as normal
Study NCT05199792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dotarem
Description: (Dotarem) (0.4 ml/kg (0.2 mmol/kg))
Study NCT00931632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.
Study NCT00931632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nitrogen gas will be administered in the same manner as the experimental drug.
Study NCT01001312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daxor Blood Volume Analysis
Description: Radiolabeled albumin for direct measurement of blood volume
Study NCT01001312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical volume status assessment
Description: Volume assessment based on history and physical examination
Study NCT03334357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAR
Study NCT03334357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Study NCT03334357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-EMS
Study NCT01351818 — intervention group
Intervention type: DRUG
Intervention: Growth Hormone
Study NCT01904890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRC Prevention and Screening Education
Description: Refer to Arm Description
Study NCT01904890 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: Refer to Arm Description
Study NCT02209363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auto-adjusting positive airway pressure
Description: nightly use for 6 months
Study NCT02209363 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Nasal dilator strips
Description: nightly use for 6 months
Study NCT03898193 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast
Description: Montelukast, 5 mg Chewable Tablets, manufactured by Pharmtechnology LLC, Republic of Belarus
Study NCT03898193 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Singulair
Description: Singulair, 5 mg Chewable Tablets, marketed by Merck Sharp \& Dohme B.V., the Netherlands
Study NCT02471573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-all protocol
Description: Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
Study NCT02471573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh transfer protocol
Description: Two embryos are selected and transferred fresh in the same cycle.
Study NCT02151617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: 40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Study NCT02151617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Study NCT02151617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: To be decided dose, tablet once daily dosing for 14 days
Study NCT02151617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet once daily dosing for 14 days
Study NCT02151617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Study NCT02151617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
Study NCT02151617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
Study NCT02151617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: Tablet, to be decided dose, once daily, 14 days
Study NCT02151617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, once daily, 14 days
Study NCT04022330 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: The blood sampling will be done just before surgery
Study NCT00053209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00053209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study NCT02758847 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Angiogram, Medtronic DCB (paclitaxel)/stent
Description: Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Each participant will receive angiogram with DCB (drug coated balloon)/stenting with wound debridement. 50% of subjects will receive an Angiogram, Medtronic DCB (paclitaxel)/stent. Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
Study NCT02758847 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Angiogram, Bard DCB (paclitaxel)/stent
Description: Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. 50% of subjects will receive 'Angiogram, Bard DCB (paclitaxel)/stent' . Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.